By Doug Busch
Reviewing past stock picks is an essential part of the investment process. It provides a valuable opportunity to assess the accuracy of our analysis, learn from both successes and setbacks, and identify lessons that can improve future decisions.
In this update, we revisit the following former stock recommendations and examine how they have performed since we first highlighted them:
-- Hyatt Hotels, written by Teresa Rivas last July. -- Sensient Technologies, introduced by Dan Victor in April. -- Harmony Biosciences, which Todd Chanko reviewed in March.
This note revisits past stock picks where new developments favor fresh buy or sell signals. Read last week's edition here.
Hyatt Hotels
The stock is up 16% year to date and 42% over the past year. It has advanced nine of the last 11 weeks and trades just 1% below its 52-week high. Peers Hilton Worldwide and Marriott International are also acting well. Hyatt stock is up 28% since our recommendation.
The daily chart continues to display notable relative strength versus the broader retail group, as reflected by its ratio chart against the benchmark State Street SPDR S&P Retail ETF since September:
A key technical development occurred May 21 when shares broke above a bullish inverse head-and-shoulders pivot at $175. The breakout also invalidated several prior bearish signals, including shooting star candles from Jan. 15 and Feb. 12, as well as back-to-back spinning tops from April 20 and April 21. Earlier, the stock reclaimed its 200-day simple moving average and completed a bullish island reversal after gapping 5% higher on April 8.
Look for a move toward $212 by year-end, 15% upside from current levels. Remain bullish above $173. Hyatt Hotels was trading around $185 Wednesday.
Sensient Technologies
The specialty ingredients company is up 21% year to date. It trades 12% below its 52-week high and is currently digesting the powerful five-week winning streak from the weeks ending between March 27 and April 24, including gains of 7%, 8%, and 23%. The stock is up 19% since our recommendation.
Looking at the daily chart, the stock showed a significant improvement in relative strength in late April, breaking above a downtrend on its ratio chart versus the benchmark State Street Materials Select Sector SPDR ETF. The move followed a well-received earnings report, with shares surging 24% on April 24:
Around the same time, the stock broke above a double-bottom trigger at $104.57, in a base eight months long. The right side of the pattern produced a bull flag. A decisive move above the $117 pivot would further confirm the breakout.
The stock recently formed a bullish golden cross, with the 50-day simple moving average crossing above the 200-day SMA. Sensient could trade toward $164 by year-end, representing 45% upside from current levels. Remain bullish above $104.57. The stock was trading around $115 Wednesday.
Harmony Biosciences Holdings
The biopharmaceutical company focused on rare neurological diseases is down 17% year to date, but has gained 8% over the past three months. It trades 24% below its 52-week high. The stock is higher by 10% since our recommendation.
Looking at the daily chart, the stock has underperformed many of its biotech peers, as reflected by its ratio chart against the State Street SPDR S&P Biotech ETF:
Shares encountered resistance near the round $40 level in December, where a series of bearish candlestick formations, including two doji candles, a dark cloud cover, and a bearish engulfing candle. Since then, the stock has entered a consolidation phase and formed a symmetrical triangle. The setup began after the stock filled a gap on Feb. 23 that originated from the Oct. 22 session.
The stock is now coiling between its 50-day and 200-day simple moving averages, and a breakout above $32.50 should trigger a buy, targeting $45 later in the second half of the year, 45% upside from current levels. Remain bullish above $29.50. Harmony Biosciences Holdings was trading around $32 Wednesday.
Doug Busch is the senior technical analyst at Barron's Investor Circle . His technical view is added to stock picks, including those published exclusively for Investor Circle readers. A glossary of technical terms is updated regularly with new entries.
-- Join us for the next live Q&A: Hear from our stock pickers and technical
analyst as we discuss the latest market developments -- and take your
questions. Register here
-- Share your questions and thoughts in the "Conversation" section below to
engage directly with the author and our community
-- Receive alerts about more content from this author by clicking "Follow"
next to the author byline at top
This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
June 04, 2026 01:14 ET (05:14 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
Comments